Copy number variations in urine cell free DNA as biomarkers in advanced prostate cancer

Yun Xia, Chiang Ching Huang, Rachel Dittmar, Meijun Du, Yuan Wang, Hongyan Liu, Niraj Shenoy, Liang Wang, Manish Kohli

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Genetic profiling of urine cell free DNA (cfDNA) has not been evaluated in advanced prostate cancer. We performed whole genome sequencing of urine cfDNAs to identify tumor-associated copy number variations in urine before and after initiating androgen deprivation therapy in HSPC stage and docetaxel chemotherapy in CRPC stage. A log2 ratio-based copy number analysis detected common genomic abnormalities in prostate cancer including AR amplification in 5/10 CRPC patients. Other abnormalities identified included TMPRSS2-ERG fusion, PTEN gene deletion, NOTCH1 locus amplification along with genomic amplifications at 8q24.3, 9q34.3, 11p15.5 and 14q11.2, and deletions at 4q35.2, 5q31.3, 7q36.3, 12q24.33, and 16p11.2. By comparing copy number between pre- and post-treatment, we found significant copy number changes in 34 genomic loci. To estimate the somatic tumor DNA fraction in urine cfDNAs, we developed a Urine Genomic Abnormality (UGA) score algorithm that summed the top ten most significant segments with copy number changes. The UGA scores correlated with tumor burden and the change in UGA score after stage-specific therapies reflected disease progression status and overall survival. The study demonstrates the potential clinical utility of urine cfDNAs in predicting treatment response and monitoring disease progression.

Original languageEnglish (US)
Pages (from-to)35818-35831
Number of pages14
JournalOncotarget
Volume7
Issue number24
DOIs
StatePublished - Jan 1 2016
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Biomarkers
Urine
DNA
docetaxel
Disease Progression
Therapeutics
Gene Deletion
Tumor Burden
Androgens
Neoplasms
Genome
Drug Therapy
Survival

Keywords

  • Cell free DNA
  • Liquid biopsy
  • Next generation sequencing
  • Prostate cancer
  • Urine

ASJC Scopus subject areas

  • Oncology

Cite this

Xia, Y., Huang, C. C., Dittmar, R., Du, M., Wang, Y., Liu, H., ... Kohli, M. (2016). Copy number variations in urine cell free DNA as biomarkers in advanced prostate cancer. Oncotarget, 7(24), 35818-35831. https://doi.org/10.18632/oncotarget.9027

Copy number variations in urine cell free DNA as biomarkers in advanced prostate cancer. / Xia, Yun; Huang, Chiang Ching; Dittmar, Rachel; Du, Meijun; Wang, Yuan; Liu, Hongyan; Shenoy, Niraj; Wang, Liang; Kohli, Manish.

In: Oncotarget, Vol. 7, No. 24, 01.01.2016, p. 35818-35831.

Research output: Contribution to journalArticle

Xia, Y, Huang, CC, Dittmar, R, Du, M, Wang, Y, Liu, H, Shenoy, N, Wang, L & Kohli, M 2016, 'Copy number variations in urine cell free DNA as biomarkers in advanced prostate cancer', Oncotarget, vol. 7, no. 24, pp. 35818-35831. https://doi.org/10.18632/oncotarget.9027
Xia, Yun ; Huang, Chiang Ching ; Dittmar, Rachel ; Du, Meijun ; Wang, Yuan ; Liu, Hongyan ; Shenoy, Niraj ; Wang, Liang ; Kohli, Manish. / Copy number variations in urine cell free DNA as biomarkers in advanced prostate cancer. In: Oncotarget. 2016 ; Vol. 7, No. 24. pp. 35818-35831.
@article{c3b942f6878b4a1292c0c8a68aa2e61e,
title = "Copy number variations in urine cell free DNA as biomarkers in advanced prostate cancer",
abstract = "Genetic profiling of urine cell free DNA (cfDNA) has not been evaluated in advanced prostate cancer. We performed whole genome sequencing of urine cfDNAs to identify tumor-associated copy number variations in urine before and after initiating androgen deprivation therapy in HSPC stage and docetaxel chemotherapy in CRPC stage. A log2 ratio-based copy number analysis detected common genomic abnormalities in prostate cancer including AR amplification in 5/10 CRPC patients. Other abnormalities identified included TMPRSS2-ERG fusion, PTEN gene deletion, NOTCH1 locus amplification along with genomic amplifications at 8q24.3, 9q34.3, 11p15.5 and 14q11.2, and deletions at 4q35.2, 5q31.3, 7q36.3, 12q24.33, and 16p11.2. By comparing copy number between pre- and post-treatment, we found significant copy number changes in 34 genomic loci. To estimate the somatic tumor DNA fraction in urine cfDNAs, we developed a Urine Genomic Abnormality (UGA) score algorithm that summed the top ten most significant segments with copy number changes. The UGA scores correlated with tumor burden and the change in UGA score after stage-specific therapies reflected disease progression status and overall survival. The study demonstrates the potential clinical utility of urine cfDNAs in predicting treatment response and monitoring disease progression.",
keywords = "Cell free DNA, Liquid biopsy, Next generation sequencing, Prostate cancer, Urine",
author = "Yun Xia and Huang, {Chiang Ching} and Rachel Dittmar and Meijun Du and Yuan Wang and Hongyan Liu and Niraj Shenoy and Liang Wang and Manish Kohli",
year = "2016",
month = "1",
day = "1",
doi = "10.18632/oncotarget.9027",
language = "English (US)",
volume = "7",
pages = "35818--35831",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "24",

}

TY - JOUR

T1 - Copy number variations in urine cell free DNA as biomarkers in advanced prostate cancer

AU - Xia, Yun

AU - Huang, Chiang Ching

AU - Dittmar, Rachel

AU - Du, Meijun

AU - Wang, Yuan

AU - Liu, Hongyan

AU - Shenoy, Niraj

AU - Wang, Liang

AU - Kohli, Manish

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Genetic profiling of urine cell free DNA (cfDNA) has not been evaluated in advanced prostate cancer. We performed whole genome sequencing of urine cfDNAs to identify tumor-associated copy number variations in urine before and after initiating androgen deprivation therapy in HSPC stage and docetaxel chemotherapy in CRPC stage. A log2 ratio-based copy number analysis detected common genomic abnormalities in prostate cancer including AR amplification in 5/10 CRPC patients. Other abnormalities identified included TMPRSS2-ERG fusion, PTEN gene deletion, NOTCH1 locus amplification along with genomic amplifications at 8q24.3, 9q34.3, 11p15.5 and 14q11.2, and deletions at 4q35.2, 5q31.3, 7q36.3, 12q24.33, and 16p11.2. By comparing copy number between pre- and post-treatment, we found significant copy number changes in 34 genomic loci. To estimate the somatic tumor DNA fraction in urine cfDNAs, we developed a Urine Genomic Abnormality (UGA) score algorithm that summed the top ten most significant segments with copy number changes. The UGA scores correlated with tumor burden and the change in UGA score after stage-specific therapies reflected disease progression status and overall survival. The study demonstrates the potential clinical utility of urine cfDNAs in predicting treatment response and monitoring disease progression.

AB - Genetic profiling of urine cell free DNA (cfDNA) has not been evaluated in advanced prostate cancer. We performed whole genome sequencing of urine cfDNAs to identify tumor-associated copy number variations in urine before and after initiating androgen deprivation therapy in HSPC stage and docetaxel chemotherapy in CRPC stage. A log2 ratio-based copy number analysis detected common genomic abnormalities in prostate cancer including AR amplification in 5/10 CRPC patients. Other abnormalities identified included TMPRSS2-ERG fusion, PTEN gene deletion, NOTCH1 locus amplification along with genomic amplifications at 8q24.3, 9q34.3, 11p15.5 and 14q11.2, and deletions at 4q35.2, 5q31.3, 7q36.3, 12q24.33, and 16p11.2. By comparing copy number between pre- and post-treatment, we found significant copy number changes in 34 genomic loci. To estimate the somatic tumor DNA fraction in urine cfDNAs, we developed a Urine Genomic Abnormality (UGA) score algorithm that summed the top ten most significant segments with copy number changes. The UGA scores correlated with tumor burden and the change in UGA score after stage-specific therapies reflected disease progression status and overall survival. The study demonstrates the potential clinical utility of urine cfDNAs in predicting treatment response and monitoring disease progression.

KW - Cell free DNA

KW - Liquid biopsy

KW - Next generation sequencing

KW - Prostate cancer

KW - Urine

UR - http://www.scopus.com/inward/record.url?scp=84978062670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978062670&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.9027

DO - 10.18632/oncotarget.9027

M3 - Article

C2 - 27127882

AN - SCOPUS:84978062670

VL - 7

SP - 35818

EP - 35831

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 24

ER -